Assistance Fund: MPS VII - Sly Syndrome

Funded
About
The Assistance Fund: MPS VII - Sly Syndrome program offers vital support to patients prescribed Mepsevii, an FDA-approved treatment. This program provides comprehensive financial assistance for copays, coinsurance, deductibles, health insurance premiums, and other medical expenses. Patients benefit from copay grant programs and financial assistance grants to alleviate financial burdens while ensuring access to necessary treatments. The Assistance Fund: MPS VII - Sly Syndrome ensures only eligible U.S. residents who meet specific criteria receive aid, offering peace of mind and accessibility to essential treatment options.
Insurance requirements: Commercially insured, Medicare / Medicaid
Enrollment Forms
Enrollment Form
Program Requirements
•Valid only for residents in the US and Puerto Rico
•Enrollment Required: Yes
•Coverage Required: No
•Needs Based: Yes
•Activation Required: No
Program Details
•Please note the following:
•1. Copay grant programs provide assistance for copays, coinsurance, and deductibles for FDAapproved treatment for the disease named in the disease program ONLY
•2. Financial assistance grant programs provide assistance for other eligible outofpocket costs, such as health insurance premiums and incidental medical expenses, in addition to copay, coinsurance, and deductible assistance on FDAapproved treatment for the disease named in the disease program
•3. This fund may cover offlabel drugs
•Copay and Financial assistance can be utilized by any innetwork pharmacy or site of care able to dispense the medication or provide treatment
•Program offers conditional approval of 30 days of immediate assistance for open programs where funding is available
•Patients will be asked to provide and verify demographic, insurance, and financial information (additional documentation may be requested)
•Approved patients will be granted assistance through the end of the calendar year unless otherwise specified for the applicable program